Vaxxas Opens World-Class Manufacturing Facility To Produce Proprietary Needle-Free Vaccine Patch For Late-Stage Clinical Trials and First Commercial Products

Vaxxas, a clinical-stage biotech company commercializing new vaccine platform technology, today announced the opening of its first state-of-the-art manufacturing facility in Brisbane, Queensland. The purpose-built 5,500-square-foot (60,000 square foot) Vaxxas Biomedical Facility will serve as the company’s global headquarters and support its expansion to produce HD-MAP vaccines for prospective late-stage clinical trials and first trials. commercial product.The Queensland Government has funded and operationally supported Vaxxas to develop the facility. Vaxxas has received additional funding from the Australian Government through the Modern Manufacturing Initiative to support the installation of specialized manufacturing and manufacturing infrastructure. This facility represents a significant investment in the future of Queensland and Australia’s biotech industries.Venerable Dr Steven Miles, Deputy Premier of Queensland, Minister of State Development, Infrastructure, Local Government and Planning and Minister of Prime Minister Support for Infrastructure for the Olympic and Paralympic Games , presided over the opening ceremony.

“Queensland is fast shaping up as a global research and innovation hub thanks to the Palaszczuk Government’s investment in state-of-the-art facilities like this one. Economic Development Queensland worked closely with Vaxxas to progress designs and approval for this facility, so it’s fantastic to be here to open it,”

“The Government is committed to supporting Queensland biomedical start-ups to scale up successfully and ensure we keep this innovation and our best and brightest researchers on home soil.

“This world-renowned technology has the potential to play a vital role in pandemic-preparedness because it allows vaccines to be deployed quickly and easily to our communities.

“Queensland is going from strength to strength as the place to work and invest in science, and Vaxxas is a fantastic example of a home-grown biotech success story that we need to retain here in Queensland. The opening of the Vaxxas Biomedical Facility in Brisbane’s Northshore is taking us one step closer to achieving that goal,”

Deputy Premier Steven Miles.

Vaxxas’ proprietary HD-MAP technology platform has the potential to improve immunization by creating vaccines that are easy to administer (potentially allowing self-administration) and can be stable at room temperature, reducing The complexity and cost associated with refrigerated delivery is required for many vaccines. vaccines are available.Vaxxas CEO David Hoey said the opening of the facility marks an important milestone for the biotech company, which was founded in 2011 on the research base of the University of Queensland.

“The Vaxxas Biomedical Facility represents a new and exciting chapter for our company, as it is foundational for our next phase of growth. With the support of the Queensland State and Australian Federal Governments, the Vaxxas Biomedical Facility will firmly position Australia at the forefront of vaccine technology innovation. The site will significantly increase our manufacturing capacity, creating new local, skilled jobs, while enabling Vaxxas to progress through late-stage clinical trials that will bring our first commercial vaccine products to the market,”

Vaxxas CEO David Hoey.

Vaxxas currently has 130 staff in its Queensland operations and plans to grow to 200 over the next three to five years. The new facility will allow Vaxxas’ R&D teams to work in tandem with production teams, expanding existing R&D work and streamlining the transition from research to eventual commercialization.The facility also provides a model for scalable product manufacturing processes that Vaxxas can replicate domestically and globally as demand for its underlying technology grows.Manufacturing will be carried out in accordance with Good Manufacturing Practice (cGMP) standards, which will also meet the requirements of the Australian Therapeutic Products Administration, the US Food and Drug Administration , the European Medicines Agency as well as other global health regulators.Successfully completed numerous human clinical trials with more than 500 participants; additional phase I clinical studies are underway for COVID-19 and seasonal flu; and other vaccine studies aimed at pandemic influenza, funded by the US Biomedical Advanced Research and Development Authority (BARDA), and a measles and rubella study by the Bill & Melinda Gates Foundation Funding, expected to begin in 2024, Vaxxas’ HD- MAP vaccine delivery platform is rapidly moving towards commercialization.